- Home
- AKA vs ZURA Comparison
AKA vs ZURA Comparison
Compare AKA & ZURA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | AKA | ZURA |
|---|---|---|
| Founded | 2018 | 2022 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Catalog/Specialty Distribution | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 116.6M | 252.9M |
| IPO Year | 2021 | N/A |
Fundamental Metrics
Financial Performance| Metric | AKA | ZURA |
|---|---|---|
| Price | $11.41 | $5.17 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 3 | 8 |
| Target Price | ★ $24.33 | $11.38 |
| AVG Volume (30 Days) | 4.1K | ★ 670.6K |
| Earning Date | 03-05-2026 | 11-13-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | ★ $595,281,000.00 | N/A |
| Revenue This Year | $5.57 | N/A |
| Revenue Next Year | $4.70 | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | ★ 5.44 | N/A |
| 52 Week Low | $7.00 | $0.97 |
| 52 Week High | $19.90 | $5.75 |
Technical Indicators
Market Signals| Indicator | AKA | ZURA |
|---|---|---|
| Relative Strength Index (RSI) | 52.97 | 61.82 |
| Support Level | $11.13 | $4.75 |
| Resistance Level | $12.12 | $5.59 |
| Average True Range (ATR) | 0.55 | 0.52 |
| MACD | 0.15 | 0.00 |
| Stochastic Oscillator | 75.24 | 66.86 |
Price Performance
Historical ComparisonAbout AKA a.k.a. Brands Holding Corp.
a.k.a. Brands Holding Corp is an online fashion retailer focused on acquiring and accelerating the growth of next-generation, digitally native fashion brands targeting Gen Z and Millennial customers. The brands of the company are two women's brands, Princess Polly and Petal & Pup, and two streetwear brands, Culture Kings and mnml. The company derives maximum revenue from Australia/New Zealand.
About ZURA Zura Bio Limited
Zura Bio Ltd is a clinical-stage, multi-asset immunology company developing novel dual-pathway antibodies for autoimmune and inflammatory diseases. It is developing three assets which have completed Phase I/Ib studies and are Phase II ready. It is developing a portfolio of therapeutic indications for tibulizumab and torudokimab with a goal of demonstrating their efficacy, safety, and dosing convenience in autoimmune and inflammatory diseases.